Author: Ferreira, Anderson J.; Murça, Tatiane M.; Fraga-Silva, Rodrigo A.; Castro, Carlos Henrique; Raizada, Mohan K.; Santos, Robson A. S.
Title: New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas Receptor Axis Document date: 2012_1_26
ID: 0qkzd2w4_21
Snippet: Imai and colleagues [37] demonstrated the role of ACE2 in ARDS pathogenesis. They found that a more severe ARDS was reached in ACE2 knockout mice, and this phenotype was reversed by double genetic deletion of the ACE2 and ACE genes or by the treatment with recombinant human ACE2 (rhACE2). Furthermore, Ang II levels were related International Journal of Hypertension to the severity of the lung injury. Of note, ACE2 is widely expressed in the pulmo.....
Document: Imai and colleagues [37] demonstrated the role of ACE2 in ARDS pathogenesis. They found that a more severe ARDS was reached in ACE2 knockout mice, and this phenotype was reversed by double genetic deletion of the ACE2 and ACE genes or by the treatment with recombinant human ACE2 (rhACE2). Furthermore, Ang II levels were related International Journal of Hypertension to the severity of the lung injury. Of note, ACE2 is widely expressed in the pulmonary endothelium, vasculature, and pneumocytes [119, 120] . Also, rhACE2 inhibited the increase of Ang II and TNF-α levels, attenuated the arterial hypoxemia and PH, and ameliorated the distribution of the pulmonary blood flow in lipopolysaccharide-induced lung injury in piglets [121] . Therefore, these studies suggest that ACE2 is a suitable target to arrest the development of ARDS in patients at risk.
Search related documents:
Co phrase search for related documents- ARDS development and blood flow: 1
- ARDS development and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55
- ARDS development and lung injury severity: 1
- ARDS development and patient ARDS development: 1, 2
- ARDS development and pulmonary endothelium: 1, 2
- ARDS pathogenesis and arterial hypoxemia: 1
- ARDS pathogenesis and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- ARDS pathogenesis and lung injury severity: 1, 2
- ARDS pathogenesis and pulmonary endothelium: 1, 2
- arterial hypoxemia and blood flow: 1, 2, 3
- arterial hypoxemia and lung injury: 1, 2, 3, 4, 5, 6, 7
- blood flow and genetic deletion: 1
- blood flow and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- genetic deletion and lung injury: 1, 2, 3
- genetic deletion and suitable target: 1
- lipopolysaccharide induce and lung injury: 1, 2, 3, 4, 5, 6
- lung injury and pulmonary endothelium: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date